- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Dr Lee on the Antitumor Activity of Rinatabart Sesutecan in FRα+ Platinum-Resistant Ovarian Cancer
Elizabeth Lee, MD, discusses the efficacy of rinatabart sesutecan in patients with FRα-expressing high-grade serous or endometrioid platinum-resistant ovarian cancer.
- 2x
- 1.75x
- 1.5x
- 1.25x
- 1x, selected
- 0.75x
- 0.5x
- Chapters
- descriptions off, selected
- captions settings, opens captions settings dialog
- captions off, selected
This is a modal window.
Beginning of dialog window. Escape will cancel and close the window.
End of dialog window.
This is a modal window. This modal can be closed by pressing the Escape key or activating the close button.
“There were…a total of 4 CRs, 2 of which are pending confirmation. With the longer duration of follow-up… the median DOR has still not yet been reached. We’re very, very encouraged by the findings so far.”
Elizabeth Lee, MD, a gynecologic oncologist and the gynecologic oncology program's liaison to the Center for Cancer Therapeutics Innovation at Dana-Farber Cancer Institute, discusses results from the dose-expansion cohort B1 of the phase 2 RAINFOLTM-01 trial (NCT05579366) evaluating the novel folate receptor alpha (FRα)–targeted antibody-drug conjugate rinatabart sesutecan (Rina-S; PRO1184) for the treatment of patients with FRα-expressing high-grade serous or endometrioid platinum-resistant ovarian cancer.